1. Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
- Author
-
Liding Zhang, Xiaohan Liang, Yanqing Li, Haiming Luo, Xuewei Du, Shiqi Niu, and Ying Su
- Subjects
Paper ,Pathology ,medicine.medical_specialty ,Gold nanoparticle ,medicine.drug_class ,Point-of-care testing ,Biomedical Engineering ,Pharmaceutical Science ,Medicine (miscellaneous) ,Bioengineering ,Monoclonal antibody ,Applied Microbiology and Biotechnology ,Mice ,Cerebrospinal fluid ,Alzheimer Disease ,Limit of Detection ,medicine ,Quantitative assessment ,Medical technology ,Animals ,Humans ,R855-855.5 ,Immunoassay ,Amyloid beta-Peptides ,business.industry ,Aβ42 monomer ,Research ,Antibodies, Monoclonal ,Paper based ,Aβ42 oligomer ,Peptide Fragments ,Visual detection ,Blood ,Point-of-Care Testing ,Elisa test ,Paper-based lateral flow immunoassay ,Magnetic nanoparticles ,Molecular Medicine ,business ,Alzheimer’s disease ,Biomarkers ,TP248.13-248.65 ,Lateral flow immunoassay ,Biotechnology - Abstract
Aβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ42 monomers (Aβ42Ms) and Aβ42Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ42 ELISA test kits usually mis-detected the elevated Aβ42Os, leading to incomplete analysis and underestimation of soluble Aβ42, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) using anti-Aβ42 monoclonal antibodies 1F12 and 2C6 for the rapid and point-of-care detection of Aβ42Ms and Aβ42Os in blood samples within 30 min for AD diagnosis. By naked eye observation, the visual detection limit of Aβ42Ms or/and Aβ42Os in dLFI was 154 pg/mL. The test results for dLFI were similar to those observed in the enzyme-linked immunosorbent assay (ELISA). Therefore, this paper-based dLFI provides a practical and rapid method for the on-site detection of two biomarkers in blood or CSF samples without the need for additional expertise or equipment. Graphical Abstract
- Published
- 2021